Ro 106-9920

Key Product Details

Product Description

Ro 106-9920 is an inhibitor of NF-κB activation, possibly via selective inhibition of LPS- and TNF-α-induced IκBα ubiquitination (IC₅₀ = 3 μM). Blocks subsequent production of TNF-α, IL-1β and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS.

Product Specifications for Ro 106-9920

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ro 106-9920

The following data is based on the product molecular weight 245.26.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.08 mL	20.39 mL	40.77 mL
5 mM	0.82 mL	4.08 mL	8.15 mL
10 mM	0.41 mL	2.04 mL	4.08 mL
50 mM	0.08 mL	0.41 mL	0.82 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Swinney A small molecule ubiquitination inhibitor blocks NF-κB-dependent cytokine expression in cells and rats. J.Biol.Chem. 2002 PMID: 11950839
• Baginski Glucocorticoid modulation of MUC5AC secretion in H292 cells. Am.Soc.Cell Biol.Abstr.
• Conalty Anticancer agents. XII. Pyridazine and benzodiazine derivatives. Proc.R.Ir.Acad.B. 1976 PMID: 967871

Product Documents for Ro 106-9920